Manchester Biotech Imperagen Raises €5.7 Million to Scale AI-Powered Enzyme Engineering Platform
Imperagen, a Manchester-based biotech company using AI and quantum physics to engineer enzymes, raised €5.7 million in Seed funding led by PXN Ventures. The company combines quantum physics simulation, AI model training, and automated robotics in a closed-loop system to improve enzyme designs. It brings total funding to €9.8 million and announced Guy Levy-Yurista as new CEO. The company plans to expand R&D, scale wet lab capabilities, and grow its go-to-market function.